The effects of corticotropin-releasing hormone (CRH) and dexamethasone on proopiomelanocortin (POMC) mRNA levels in cultured pituitary adenoma cells were studied in 10 patients with Cushing's disease. As a control, POMC mRNA levels in cells from nonadenomatous tissues were examined in four patients. Human POMC mRNA in the cells was analyzed by Northern blot hybridization. Human POMC DNA probe hybridized with only a single size class of RNA (approximately 1,200 nucleotides) from the adenoma and nonadenoma cells of each patient. The size of POMC mRNA did not change through the culture or after incubation with CRH or dexamethasone. CRH increased POMC mRNA levels in these cells in a dose- and time-dependent manner. The minimum concentration of CRH required to elevate POMC mRNA levels in these cells exposed for 15 h was 0.1 nM. The minimum duration of 1 nM CRH treatment required to increase these levels was 3 h under our conditions. Inhibitory effects of 1 and 10 micrograms/dl dexamethasone on ACTH release and POMC mRNA levels in nonadenoma cells were greater than those in adenoma cells. These results suggest the following: (a) that the mRNA in cultured pituitary adenoma cells is qualitatively the same as that in vivo; (b) that responses of mRNA levels to CRH are time- and dose-dependent; and (c) that adenoma cells resist the inhibitory effect of dexamethasone on POMC mRNA levels and ACTH release.
T Suda, F Tozawa, M Yamada, T Ushiyama, N Tomori, T Sumitomo, Y Nakagami, H Demura, K Shizume
Title and authors | Publication | Year |
---|---|---|
The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.
Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M |
International journal of molecular sciences | 2022 |
Molecular Mechanisms of Glucocorticoid Resistance in Corticotropinomas: New Developments and Drug Targets
D Ciato, A Albani |
Frontiers in Endocrinology | 2020 |
Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles
MF Cassarino, AG Ambrogio, A Cassarino, MR Terreni, D Gentilini, A Sesta, F Cavagnini, M Losa, FP Giraldi |
Journal of Neuroendocrinology | 2018 |
Prevention, diagnosis and treatment of Nelson's syndrome
E Sala, H Allen, TD Azad, A Veeravagu, L Katznelson |
2018 | |
Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations
E Daniel, J Newell-Price |
F1000Research | 2017 |
Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas
MF Cassarino, A Sesta, L Pagliardini, M Losa, G Lasio, F Cavagnini, FP Giraldi |
Endocrine | 2016 |
Locomotor sensitization to EtOH: contribution of β-Endorphin
S Dempsey, JE Grisel |
Frontiers in molecular neuroscience | 2012 |
Responses to Corticotrophin-Releasing Hormone and Dexamethasone in a Large Series of Human Adrenocorticotrophic Hormone-Secreting Pituitary Adenomas In Vitro Reveal Manifold Corticotroph Tumoural Phenotypes : Secretory pattern in corticotroph tumours in vitro
FP Giraldi, L Pagliardini, MF Cassarino, M Losa, G Lasio, F Cavagnini |
Journal of Neuroendocrinology | 2011 |
The Pituitary
X Bertagna, L Guignat, MC Raux-Demay, B Guilhaume, F Girard |
The Pituitary | 2011 |
Responses to Corticotrophin-Releasing Hormone and Dexamethasone in a Large Series of Human Adrenocorticotrophic Hormone-Secreting Pituitary Adenomas In Vitro Reveal Manifold Corticotroph Tumoural Phenotypes: Secretory pattern in corticotroph tumours in vitro
FP Giraldi, L Pagliardini, MF Cassarino, M Losa, G Lasio, F Cavagnini |
Journal of Neuroendocrinology | 2011 |
Pituitary development and physiology
CC Cheung, RH Lustig |
Pituitary | 2007 |
Medical management of pituitary adenomas: structural and ultrastructural changes
Sylvia L Asa, Shereen Ezzat |
Pituitary | 2003 |
The Role of Hormones, Growth Factors and Their Receptors in Pituitary Tumorigenesis
S Ezzat |
Brain Pathology | 2001 |
Animal Models of CRH Deficiency
M Venihaki, JA Majzoub |
Frontiers in Neuroendocrinology | 1999 |
The Corticotropin-Release Inhibitory Factor Hypothesis: A Review of the Evidence for the Existence of Inhibitory as Well as Stimulatory Hypophysiotropic Regulation of Adrenocorticotropin Secretion and Biosynthesis*
D Engler, E Redei, I Kola |
Endocrine reviews | 1999 |
The Cytogenesis and Pathogenesis of Pituitary Adenomas*
SL Asa, S Ezzat |
Endocrine reviews | 1998 |
Cushing's Syndrome
DN Orth |
New England Journal of Medicine | 1995 |
Central administration of saikosaponin-d increases corticotropin-releasing factor mRNA levels in the rat hypothalamus
I Dobashi |
Neuroscience Letters | 1995 |
Corticotropin-releasing hormone, proopiomelanocortin, and glucocorticoid receptor gene expression in adrenocorticotropin-producing tumors in vitro
T Suda, F Tozawa, I Dobashi, N Horiba, N Ohmori, M Yamakado, M Yamada, H Demura |
Journal of Clinical Investigation | 1993 |
Recombinant DNA Technologies in Neuroendocrinology
H Imura |
1993 | |
Opioids
A Herz, H Akil, EJ Simon |
1993 | |
Unrestrained production of proopiomelanocortin (POMC) and its peptide fragments by pituitary corticotroph adenomas in Cushing's disease
X Bertagna |
The Journal of Steroid Biochemistry and Molecular Biology | 1992 |
Neurobiology of Opioids
OF Almeida, TS Shippenberg |
1991 | |
CORTICOTROPHIN RELEASING FACTOR IN MAN AND ITS MEASUREMENT: A REVIEW
EA Linton, PJ Lowry |
Clinical Endocrinology | 1989 |
Cushing’s Syndrome
DT Kishi |
Journal of the American Pharmaceutical Association (1961) | 1975 |
Cushing's disease
EJ Carry, I Walzer |
The American Journal of Surgery | 1960 |